Skip to main content
Rady School of Management Rady School of Management
  1. HOME
  2. Why Rady
  3. Dean’s Office
  4. Dean's Advisory Council
  5. Steve Prestrelski

Steve Prestrelski

Founder and Chief Scientific Officer, Xeris Pharmaceuticals

Steven (Steve) Prestrelski, MBA ’06 is the Founder and Chief Scientific Officer of Xeris Pharmaceuticals who invented the Xeris platform technologies. Dr. Prestrelski is an internationally recognized expert in drug formulation and delivery, with over 30 years of drug development experience.

Prior to founding Xeris, Dr. Prestrelski was the Executive Director of the Bydureon program at Amylin Pharmaceuticals, leading the program from Phase 2 through global regulatory filings.  He then transitioned to the role of Vice President of Pharmaceutical R&D.

Before working at Amylin, Dr. Prestrelski was Vice President of Biopharmaceuticals at PowderJect Technologies, Inc., where he pioneered the delivery of solid biopharmaceuticals. Additionally, Dr. Prestrelski has worked with Alza and Amgen in technical and management roles.

Dr. Prestrelski served on the Board of Directors of BaroFold, Inc. and on the Scientific Advisory Board of iMEDD, Inc., a Bay Area drug delivery company. Dr. Prestrelski has published over 60 invited book chapters and peer-reviewed journal articles. He also has over 30 issued and 40 pending patent applications in the field of drug development, formulation, and delivery, with over 100 globally.

Dr. Prestrelski holds a PhD in Molecular Biophysics from the City University of New York and an MBA from the Rady School of Management at the University of California, San Diego.